Day: April 23, 2025

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader:         Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Anexo Group plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Financial Adviser to DBAY(d)        Date dealing undertaken: 22nd April 2025(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state...

Alm. Brand Group hereby publish consensus estimates prior to the announcement of the Q1 results. Consensus estimates are also available via: almbrand.dk Conference Call Alm. Brand Group will report its Q1 2025 results on May 1 at 07:30 CET and host a conference call with management at 11:00 CET on the day of release. Dial in for analysts and investors (pincode: 743033): Denmark: +45 89 87 50 45 UK: +44 20 3936 2999 USA: +1 646 664 1960 Contact Please direct any questions regarding this announcement to: Investors and equity analysts:                          Mads Thinggaard – Head of IR, Rating & ESG Reporting – mobile no. +45 2025 5469                                                                                               Press:                                                                                           ...

Press release23 April 2025 – N° 08 Philipp Rüede appointed CEO SCOR L&H and Member of SCOR’s Executive Committee We are pleased to announce Philipp Rüede as the new CEO SCOR Life & Health and a Member of the Executive Committee. Philipp is replacing Frieder Knüpling who stepped down in July 2024. Philipp’s immediate priorities will be to drive the L&H new business strategy, to protect and deliver the in-force value, and to improve the cash profile of the L&H business, in line with the updated L&H strategy unveiled at our Investor Day in December 2024. Philipp Rüede, a dual Swiss and German citizen, is a graduate of the Ecole Polytechnique in Paris and holds a Master’s degree in Engineering from the Swiss Federal Institute of Technology (ETH Zürich). He has more than 20 years of experience in Banking and Reinsurance....

Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7 – 10, 2025 in Amsterdam, Netherlands. The following abstracts will be presented as posters in the Viral Hepatitis B and D: New Therapies, Unapproved Therapies or Strategies session on May 8, 2025, from 8:30 am – 5:00 pm CET. Abstract Number: 1768Title: IM-PROVE I: characterization of chronic hepatitis B (CHB) subjects with functional cure or HBV DNA suppression after completion of imdusiran...

2025 First Quarter SalesPress release – Paris, April 23, 2025, at 7:30am CEST Strong start to the year,demonstrating the relevance of our health-oriented portfolioStrong Q1 2025, with sales of €6,844m, up +4.3% on a like-for-like (LFL) basis Contributions from both volume/mix (+1.9%) and price (+2.4%); positive volume/mix again in all categories Broad-based growth, demonstrating the resilience of our businessVery strong performance in China, North Asia & Oceania, in all categories Solid growth in North America, led by a continued, winning momentum in High Protein Consistent progress in Europe with solid volume/mix2025 guidance confirmed, in line with mid-term ambition: LFL sales growth expected between +3% and +5%, with recurring operating income growing faster than sales€ millionexcept % Q12024 Q12025 Reported...

23 April 2025: Borregaard ASA (”Borregaard”, OSE ticker: BRG) Presentation of Q1 2025 results Borregaard will report first quarter 2025 results on Wednesday 30 April 2025 at 07:00 CEST. A stock exchange announcement will be made. A press release, the quarterly report and a presentation will be made available on https://www.borregaard.com/investors/. A presentation of the first quarter 2025 results will also be held at 08:30 CEST at SEB, Filipstadveien 10, Bygg B, Oslo. Attendance in person is possible. The presentation can be followed live on web-TV at https://www.borregaard.com/investors/. It will be possible to ask questions via the web. All presentations will be held in English. For more information about Borregaard ASA, please visit https://www.borregaard.com/. Contact:Lotte Kvinlaug, Investor Relations Officer, +47 922 86 909 This...

First quarterOrder intake for the first quarter increased by 97% to SEK 930 m (473). Organically, order intake increased by 12%, acquired growth was 89% and currency effects impacted by -4% Net sales increased by 44% to SEK 890 m (616). Organically, net sales decreased by 17%. Acquired growth was 59% and currency translations impacted by 2% Adjusted EBIT reached SEK 218 m (137), equal to a 24.5% (22.2) adjusted operating margin EBIT reached SEK 175 m (130), equal to a 19.6% (21.1) operating margin Adjusted profit after tax totaled SEK 159 m (113) and adjusted basic earnings per share was SEK 3.17 (2.43) Profit after tax totaled SEK 115 m (107) and basic earnings per share was SEK 2.29 (2.28) Cash flow from operating activities amounted to SEK 187 m (58) New organizational structure from 2025 to strengthen customer focus and cross-sellingLast...